An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.
Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T.
Lohse S, et al.
Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3.
Cancer Res. 2016.
PMID: 26634925